Verbatim response from ChatGPT
Short answer
- Expect meaningful weight loss over months, not days. Typical ranges from clinical trials: ~5–15% body weight after ~6–12 months on approved GLP‑1 drugs (semaglutide, liraglutide), and up to ~20% or more with the newer GIP/GLP‑1 tirzepatide in some studies. Individual results vary a lot.
- Weight loss is usually fastest in the first 3–6 months and then slows or plateaus. If you stop the medication, much or all of the lost weight often comes back — so many people need a long‑term plan if they want to keep the weight off.
Why those numbers
- Semaglutide (Wegovy for weight management; Ozempic is the same molecule for diabetes) in the STEP trials produced average losses around ~10–15% at ~68 weeks for many participants.
- Liraglutide (Saxenda) produces smaller average losses (roughly mid‑single digits to low‑teens percent after about a year in trials).
- Tirzepatide (Zepbound for weight management; Mounjaro as the diabetes formulation) in SURMOUNT trials produced the largest average losses reported to date — up to ~20%+ at higher doses over ~72 weeks for some groups.
What to expect day‑to‑day and month‑to‑month
- Early weeks: appetite suppression and some rapid early loss (partly water, less food intake).
- Months 1–6: biggest sustained decline in weight for most people. Many lose several percent of body weight per month early on, then rate slows.
- After ~6–12 months: loss plateaus. Continued treatment can further reduce weight slowly or help maintain the loss; stopping commonly leads to regain.
Is it sustainable?
- Medication alone: weight tends to come back after stopping because the drugs change appetite and physiology while you take them. Trials that stopped active drug saw participants regain substantial weight.
- Best chance for lasting benefit: combine medication with durable lifestyle changes (nutrition habits, physical activity, behavioral therapy), treat underlying conditions, and have a long‑term maintenance plan. Some people take GLP‑1s long term under medical supervision to maintain weight loss if appropriate.
Risks and practical issues
- Common side effects: nausea, vomiting, constipation/diarrhea, decreased appetite. Less common but serious: gallbladder problems, pancreatitis, rare thyroid concerns — discuss with your clinician.
- Cost and insurance: many GLP‑1s are expensive and insurance coverage varies; Wegovy and Zepbound are weight‑management approvals, but access can be limited.
- Not for pregnancy or thinking of becoming pregnant.
Which drugs/brands to know about
- Wegovy (semaglutide) — strong evidence for weight loss, once‑weekly injection, FDA‑approved for obesity.
- Ozempic (semaglutide) — diabetes formulation used off‑label by some for weight loss.
- Zepbound (tirzepatide) and Mounjaro (tirzepatide) — very strong weight‑loss results in trials; Zepbound is the weight‑loss indication.
- Saxenda (liraglutide) — older option, daily injection, smaller average effect than semaglutide/tirzepatide.
Next steps I recommend
- Talk with your primary care doctor or an obesity specialist about: medical suitability, goals (how much % body weight you want to lose), comorbidities, and monitoring.
- Ask about a combined plan that includes dietary support and activity and clarify expected timelines and costs.
- If you want, tell me your starting weight and goals and I can offer a realistic example of how much weight you might expect to lose in 3, 6, and 12 months on a typical GLP‑1 treatment path.